A randomized controlled study of esketamine combined with SSRI in the treatment of inpatients with severe depression with agitation

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000038915

Enrollment

Unknown

Registered

2020-10-10

Start date

2020-11-01

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depression

Interventions

Test group:Esketamine+SSRI

Control group:SSRI

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-65 years old; 2. The patients who met the diagnostic criteria of severe depressive episode in ICD-10; 3. Those who scored 1 or more in the agitation item of Hamilton Depression scale-17 (HAMD-17); 4. Those patients who were fully informed and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with organic diseases that can cause agitation; 2. Patients with comorbid neurosis, stress-related and somatoform disorders; 3. Patients with a history of material dependence; 4. Patients with brain organic diseases; 5. Patients with depression is caused by other organic diseases or drugs; 6. Patients who have been treated with racemic ketamine; 7. Patients who are contraindicated to use esmketamine.

Design outcomes

Primary

Measure	Time frame
HAMD-17;CADSS;TESS;	—

Countries

China

Contacts

Public ContactSong Hui

The Third People's Hospital of Mianyang City

182321767@qq.com+86 15892628201

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026